Split-course chemoradiotherapy with S-1, a novel oral fluorouracil, and cisplatin for distant metastases of oesophageal cancer stage IVb
Journal Title: Journal of Cancer Research & Therapy - Year 2017, Vol 5, Issue 1
Abstract
Objectives: To evaluate the efficacy and safety of split-course chemoradiotherapy with S-1, a novel oral fluorouracil, together with cisplatin in patients with distant oesophageal cancer stage IVb metastasis. Methods: Forty-one patients with distant oesophageal cancer metastasis and performance status 0 or 1 received split-course chemoradiotherapy with S-1 and cisplatin. All 41 patients were reviewed retrospectively. Chemoradiotherapy comprised two courses of 30-Gy radiotherapy over three weeks plus daily oral S-1 (70mg/m2/day) for two weeks and a 24 h cisplatin infusion (70mg/m2) on Day 8, with a two week interval between the two courses. Results: The most frequent adverse events (AEs) were grade 3 and 4 neutropenia (29.2%), thrombocytopenia (9.8%), and anaemia (7.3%). Non-haematological AEs were generally mild. AEs in the initial course of chemoradiotherapy remitted during the second interval week. Overall, the complete response rate was 22.0% and endoscopic complete response rate for primary lesion was 65.9%. Thirty-one patients (75.6%) became asymptomatic and regained normal swallowing function. The overall median survival time was 12 months. Conclusion: This retrospective investigation showed that split-course chemoradiotherapy with S-1 and cisplatin had an encouraging safety profile together with good efficacy. Potentially, this regimen may become a standard for distant metastasis of oesophageal cancer stage IVb.
Authors and Affiliations
Hiroaki Iwase, Masaaki Shimada, Noboru Hirashima, Nobumitsu Ryuge, Momoko Goto, Takashi Kondo, Daiki Tanaka, Satoshi Unita, Eriko Kato
Keywords
Related Articles
- EP ID EP535755
- DOI 10.14312/2052-4994.2017-1
- Views 67
- Downloads 0
Colorectal cancer: Ageing, myeloid-derived suppressor cells, and treatment: Report of two cases
Background: Colorectal cancer (CRC) is the third cause of cancer in the world and age is a risk factor for this disease. Treatments such as surgical resection and adjuvant chemotherapy have increased the mean survival an...
18F-FDG PET/CT for first follow-up post chemotherapy in lymphoma: Is it mandatory to do whole body scan?
Objective: To assess the feasibility of 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) scan limited to the original sites of lymphoma in 1st follow-up (F/U) post-chemotherapy...
Inhibition of glycolysis and growth of colon cancer cells by 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) in combination with butyrate, 2-deoxy glucose, 3-bromopyruvate or biguanides
Introduction: Glycolysis shows a positive correlation with growth of human colon cancer cells. PFKFB3 is an important enzyme regulating glycolysis in many tumor cells and presents a target for cancer chemotherapy. We stu...
Development of a new formulation of interferons (HEBERPAG) for BCC treatment
Purpose: This work is aimed to show briefly, the clinical development of a new pharmaceutical formulation of interferons for the treatment of basal cell carcinoma. Methods: A rationale design of the combination of IFN-α2...
The clinical and biological implications of the focal adhesion kinase pathway in ShenLingLan mediated suppression of cellular migration of ovarian cancer cells
The incidence of ovarian cancer in the UK has increased by almost twenty percent since the 1970’s and the majority of cases are not diagnosed until the late stages, when metastasis is more likely to have occurred. Focal...